Dual Approvals and a Tariff Overhang: Eli Lilly’s Mixed Signal to the Market
12.06.2026 - 17:56:57 | boerse-global.de
Eli Lilly won two FDA approvals in a single day, yet its shares slipped as fresh worries about US pharmaceutical import tariffs dampened investor enthusiasm. The disconnect between regulatory success and market reaction underscores the competing forces at play for the drugmaker: powerful pipeline momentum on one side, and geopolitical risk on the other.
The standout approval was for Foundayo (orforglipron), the first oral GLP-1 medication specifically cleared for obesity. Unlike existing injectable therapies or pills that require strict fasting protocols, Foundayo is a small-molecule drug taken once daily without food or drink restrictions. Phase 3 data showed patients lost an average of 8.7% of body weight over 36 weeks, with extended ATTAIN-1 and ATTAIN-2 trials over 72 weeks producing even sharper results — up to 14.4% weight loss in premenopausal women and 14.1% in postmenopausal women. Analysts project that oral GLP-1 alternatives could capture around 20% of the market by 2030, driven by simpler logistics and the elimination of cold-chain requirements.
The second regulatory nod was for a new dosing regimen for Ebglyss (lebrikizumab), Lilly’s treatment for moderate-to-severe atopic dermatitis. Patients who respond to initial therapy now need an injection only every eight weeks — six shots per year — compared with the previous monthly schedule. The decision was backed by long-term data from the ADjoin Phase 3 study involving more than 1,600 patients, which showed a stable safety profile with the most common side effects being conjunctivitis and injection-site reactions.
Despite these milestones, the stock fell 1.18% on Friday to €992.40, retreating from its 52-week high of €1,044 reached just days earlier. That high is now roughly 5% away. Reports that the US is considering import tariffs on pharmaceutical goods have rattled the entire sector, as the policy aims to bring drug manufacturing back to American soil. Lilly, however, is relatively insulated: about 71% of its assets and 68% of its revenue come from the US.
Should investors sell immediately? Or is it worth buying Eli Lilly?
The tariff talk contrasts sharply with the company’s clinical momentum. In a direct Phase 3 head-to-head trial, orforglipron trounced Novo Nordisk’s comparable GLP-1 tablet. Patients with diabetes saw their long-term blood sugar drop by 2.2 percentage points, versus 1.4 points for Novo Nordisk’s drug. Weight loss also favored Lilly: 9.2% of body weight lost on average, compared with 5.3%. The convenience of no fasting requirements gives it a clear edge in everyday use.
That commercial promise is already showing up in the financials. First-quarter revenue surged more than 55% to $19.8 billion, fueled by Mounjaro and Zepbound sales. Management raised its full-year revenue guidance to as much as $85 billion — a figure that also aligns with the 2026 forecast of $82 billion to $85 billion reaffirmed separately, supported by those same injectables. To keep up with demand, Lilly has poured over $50 billion into US production facilities since 2020.
The stock closed at €1,004.20 on Thursday, narrowly below its 52-week high, and has gained 15.76% over the past month. However, the relative strength index sits at 70, signaling an overbought condition. Perhaps reflecting that, Vice President Ilya Yuffa sold 2,500 shares at $1,150.77 each this week under a pre-arranged trading plan.
Eli Lilly at a turning point? This analysis reveals what investors need to know now.
Beyond the near-term approvals, Lilly’s pipeline continues to expand. Retatrutide, a triple agonist, delivered a 28.3% weight reduction over 80 weeks at the highest dose in the TRIUMPH-1 Phase 3 study — far exceeding previous GLP-1 results. Meanwhile, orforglipron is being tested for major depression and sleep apnea, and international approval for Foundayo is expected by the end of the second quarter of 2026. If those new indications materialize, Lilly could cement its dominance in metabolic medicine well into the next decade.
Ad
Eli Lilly Stock: New Analysis - 12 June
Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
